J.-L. Gomez - Concepedia

Author

J.-L. Gomez

Also Known As

J Gomez, J L Gomez, J-L. Gomez, J. Gomez, J. L. Gomez, J.-L. Gomez, J.L. Firvida Gomez, J.L. Gomez, Jorge Andres Abreu Gomez

Publications

671

Citations

H-Index

Concepts

All Affiliations

Université Laval Endocrinology Research Center Centre hospitalier universitaire de Québec

About

J.-L. Gomez is an author at Université Laval specializing in medicine, urology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	632
2	Endocrinology	4	4	453
3	Metabolism	3	3	467
4	Health Sciences	1	1	29
5	Molecular Medicine	1	1	29

J.-L. Gomez

Publications

632

Citations

H-Index

Page 1

	Year	Citations
Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. A. Bèlanger, Bernard Candas, A. Dupont, The Journal of Clinical Endocrinology & Metabolism Reproductive EndocrinologyAdrenal GlandTesticular SteroidsUnconjugated SteroidsDhea Formation	1994	401
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Fernand Labrie, A Dupont, L. Cusan, PubMed Surgical OncologyOncologyUrologyNeoadjuvant TherapyGenitourinary Cancer	1993	113
Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women Fernand Labrie, A. Bèlanger, Claude Labrie, The Journal of Steroid Biochemistry and Molecular Biology Hormonal ContraceptivePercutaneous DehydroepiandrosteroneMedicineGynecologyMenopausal Hormone Therapy	2007	37
Metabolic Effects of 12-Month Percutaneous Dehydroepiandrosterone Replacement Therapy in Postmenopausal Women P. Diamond, L. Cusan, J.-L. Gomez, Obstetrical & Gynecological Survey NeuroendocrinologyGynecologyMetabolic SyndromeSteroid MetabolismHealth Sciences	1997	29
Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. Fernand Labrie, L. Cusan, J.-L. Gomez, PubMed UrologyOncologySurgical OncologyGenitourinary CancerLhrh Agonist	1995	29
Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy Theodorus van der Kwast, Bernard Têtu, Yves Fradet, The Prostate Androgen ReceptorSurgical OncologyAr ExpressionGynecologyPathology	1996	13
Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer. Fernand Labrie, A Dupont, L. Cusan, PubMed PharmacotherapySurgeryAntiandrogen FlutamideEndocrine OncologyMajor Advantages	1993	10

Page 1